However, the transmembrane activator and calcium modulator and cyclophilin ligand interactor-immunoglobulin (TACI-Ig or atacicept) treatment blocking APRIL and BAFF signaling and plasmablast/plasma cells maturation (Figure 3) was a failure in MS, resulting in exacerbation of relapse rate [138]. Here, TNFRSF13B is linked to myeloid sarcoma.